Intermediate embryonic stem cell type could lead to advances in regenerative medicine

A team led by UT Southwestern has derived a new “intermediate” embryonic stem cell type from multiple species that can contribute to chimeras and create precursors to sperm and eggs in a culture dish.

The findings, published online this week in Cell Stem Cell, could lead to a host of advances in basic biology, regenerative medicine, and reproductive technology.

Cells in early embryos have a range of distinct pluripotency programs, all of which endow the cells to create various tissue types in the body, explains study leader Jun Wu, Ph.D., assistant professor of molecular biology.

A wealth of previous research has focused on developing and characterizing “naïve” embryonic stem cells (those about four days post-fertilization in mice) and “primed” epiblast stem cells (about seven days post-fertilization in mice, shortly after the embryo implants into the uterus).

However, says Wu, there’s been little progress in deriving and characterizing pluripotent stem cells (PSCs) that exist between these two stages – largely because researchers have not been able to develop a paradigm for maintaining cells in this intermediate state.

Cells in this state have been thought to possess unique properties: the ability to contribute to intraspecies chimeras (organisms that contain a mix of cells from different individuals of the same species) or interspecies chimeras (organisms that contain a mix of cells from different species) and the ability to differentiate into primordial germ cells in culture, the precursors to sperm and eggs.

For this study, the researchers successfully created intermediate PSCs, which they named “XPSCs” from mice, horses, and humans.

Wu says that these results could eventually lead to an array of advances in both basic and applied research. For example, looking at gene activity in XPSCs from different species and interspecies chimeras could help researchers understand which signatures have been conserved through evolution.

Examining the communication between cells in chimeras may help scientists identify strategies that could be used to accelerate the development of tissues and organs from stem cells used for transplantation.

And using chimera-derived primordial germ cells to create sperm and eggs could aid in preserving endangered animal species and advancing infertility treatments.

These XPSCs have enormous potential. Our study helps open the door to each of these possibilities.”


Jun Wu, PhD, Study Leader and Assistant Professor of Molecular Biology, Virginia Murchison Linthicum Scholar in Medical Research, UT Southwestern Medical Center

Wu notes that developing XPSCs presented a special challenge because the conditions that keep naïve PSCs in a stable state are exactly the opposite of those that stabilize primed PSCs.

While culture conditions for naïve PSCs must activate a WNT cell-signaling pathway and suppress the FGF and TGF-ß pathways, the conditions to maintain primed PSCs must suppress WNT and activate FGF and TGF-ß.

Aiming for the preferred environment for XPSC derivation, Wu and his colleagues placed cells from early mouse embryos into cultures containing chemicals and growth factors that activate all three pathways.

These lab-grown cells were extremely stable in culture and able to multiply

Read more

Development of new stem cell type may lead to advances in regenerative medicine

IMAGE

IMAGE: Drs. Jun Wu, Leqian Yu, Yulei Wei and colleagues isolated a new type of pluripotent stem cell from mice, horses, and humans, named XPSCs, which are capable of generating chimeras…
view more 

Credit: Photo illustration by Leqian Yu

DALLAS – Dec. 3, 2020 – A team led by UT Southwestern has derived a new “intermediate” embryonic stem cell type from multiple species that can contribute to chimeras and create precursors to sperm and eggs in a culture dish.

The findings, published online this week in Cell Stem Cell, could lead to a host of advances in basic biology, regenerative medicine, and reproductive technology.

Cells in early embryos have a range of distinct pluripotency programs, all of which endow the cells to create various tissue types in the body, explains study leader Jun Wu, Ph.D., assistant professor of molecular biology. A wealth of previous research has focused on developing and characterizing “naïve” embryonic stem cells (those about four days post-fertilization in mice) and “primed” epiblast stem cells (about seven days post-fertilization in mice, shortly after the embryo implants into the uterus).

However, says Wu, there’s been little progress in deriving and characterizing pluripotent stem cells (PSCs) that exist between these two stages – largely because researchers have not been able to develop a paradigm for maintaining cells in this intermediate state. Cells in this state have been thought to possess unique properties: the ability to contribute to intraspecies chimeras (organisms that contain a mix of cells from different individuals of the same species) or interspecies chimeras (organisms that contain a mix of cells from different species) and the ability to differentiate into primordial germ cells in culture, the precursors to sperm and eggs.

For this study, the researchers successfully created intermediate PSCs, which they named “XPSCs” from mice, horses, and humans.

Wu says that these results could eventually lead to an array of advances in both basic and applied research. For example, looking at gene activity in XPSCs from different species and interspecies chimeras could help researchers understand which signatures have been conserved through evolution. Examining the communication between cells in chimeras may help scientists identify strategies that could be used to accelerate the development of tissues and organs from stem cells used for transplantation. And using chimera-derived primordial germ cells to create sperm and eggs could aid in preserving endangered animal species and advancing infertility treatments.

“These XPSCs have enormous potential. Our study helps open the door to each of these possibilities,” says Wu, who is a Virginia Murchison Linthicum Scholar in Medical Research.

Wu notes that developing XPSCs presented a special challenge because the conditions that keep naïve PSCs in a stable state are exactly the opposite from those that stabilize primed PSCs. While culture conditions for naïve PSCs must activate a WNT cell-signaling pathway and suppress the FGF and TGF-ß pathways, the conditions to maintain primed PSCs must suppress WNT and activate FGF and TGF-ß.

Aiming for the preferred environment for XPSC derivation, Wu and his

Read more

Sports Medicine Market Analysis by Applications, End-Users, Top Companies, Future Growth Opportunities, Product Type, Global Forecast To 2020

The MarketWatch News Department was not involved in the creation of this content.

Japan, Japan, Wed, 02 Dec 2020 14:20:31 / Comserve Inc. / — Over the years, the sports medicine market has witnessed various technological advancements made to ensure and provide better recovery and rehabilitative measures for injuries caused during sports or physical activities.

The sports medicine market comprises products and devices used by professional or non-professional athletes or sportspersons to prevent and protect themselves from injuries as well as devices that enhance performance. The sports medicine products play an important role in the rehabilitation, recovery, protection, endurance, and monitoring of athletes while playing sports. Over the years, the sports medicine market has witnessed various technological advancements made to ensure and provide better recovery and rehabilitative measures for injuries caused during sports or physical activities.

These advancements have led to the development of new products and therapies to treat sports injuries. Various market players are focusing on the introduction of newer products and treatment options for sports injuries. A number of key players are competing to secure larger shares of the market by launching new products. Arthrex, Inc. (U.S.), Smith & Nephew PLC (U.K.), DePuy Synthes Companies (U.S.), Stryker Corporation (U.S.), and CONMED Corporation (U.S.) are the top five players of this market

Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-61031

“The Final Report will cover the impact analysis of COVID-19 on this industry (Global And Regional Market).”

In 2015, the body reconstruction & repair products segment is expected to account for the largest share of the global sports medicine market, by product, while the knee injuries segment is expected to account for the largest share of the sports medicine market, by application.

In 2015, North America is expected to account for the largest share of the global sports medicine market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). In the coming years, the sports medicine market is expected to witness the highest growth rate in the Asia-Pacific region, with emphasis on India, China, and Japan. The entry of international players, increasing government initiatives, and rising awareness regarding sports medicine in emerging nations like India and China are expected to drive the market in these regions.

The sports medicine market witnesses high competitive intensity as there are several big and many small firms with similar product offerings. These companies adopt various growth strategies (agreements, partnerships, joint ventures, geographic expansions, new product launches, and acquisitions) to increase their market shares and establish a strong foothold in the global market.

“The Final Report will cover the impact analysis of COVID-19 on this industry (Global And Regional Market).”

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market

Read more

The Best Type Of Nut And Seed Butter For Bodybuilders

The idea of good food is different for everyone. 

Regardless of whether you stick to the good old paranthas or go for a more Insta-friendly bowl of smoothie, you’re no stranger to the long list of superfoods. And nuts and seeds are at the top of it. 

Even in the form of butter, these protein-packed, healthy fat-rich powerhouses can fill you up real nice.  

The world of nut and seed butter is so much bigger than plain ol’ peanut butter and we want to tell you all about it especially if you’re into muscle building.

Peanut Butter

2 tablespoons of peanut butter contain 8 gms of protein which is equal to 2 boiled egg whites. If that wasn’t impressive enough, peanuts can also contribute a handful of vitamins and minerals like niacin, folate, vitamin E, magnesium, zinc and iron to your diet. 

How Much Should You Eat

The benefits of peanut butter are plenty and considering that it is a healthy high-fat food, a serving of 2 tablespoons per day is enough. The same can be altered based on your fitness goals and personal diet.

Almond Butter

Almond butter has about 6.8 gms of protein in a serving of 2 tablespoons. It’s relatively low in protein but it makes up for it by being a good source of omega-3 fatty acid, vitamin E, calcium, magnesium and manganese, fibre, copper and phosphorous. It’s also rich in monosaturated fats that can do a bang on job of reducing bad cholesterol and raising the good one.

How Much Should You Eat

The recommended dose is 2 tablespoons per day. 

Cashew Butter

This one is a bit lower in protein and fats compared to the others but cashews contain plenty of vitamins and minerals like calcium, iron, magnesium, potassium and zinc. 2 tablespoons of cashew butter contains nearly 5.6 gms of protein. This super creamy one is good for blood pressure, sugar and cholesterol control, bone health, the immune system and metabolism.

How Much Should You Eat

Anywhere between 2-3 tablespoons of cashew butter is good enough to make your day.

Hazelnut Butter

Although hazelnut butter is high in calories, it does provide other nutrients and healthy fats. This addictive nut butter is rich in vitamin B6, phosphorus, folic acid, zinc and potassium. It relieves inflammation and if you workout on a daily basis, it provides you with enough healthy fats to maintain strength and lose the extra fat.

How Much Should You Eat

Remember to not eat too much of this one if you’re trying to lose weight. You can add ½ to 1 tablespoon of hazelnut butter to your smoothie bowl once a day. 

Sunflower Seed Butter

Allergic to nuts? No worries. Sunflower seed butter has got your back. It contains the same amount of protein as peanut and almond butter and it’s equally high in vitamin E, vitamin B6, magnesium, phosphorous and zinc.

How Much Should You Eat

Adding 2 tablespoons of sunflower seed butter to your daily high-protein diet will

Read more

Type 2 diabetes drug metformin recalled over contamination with possible carcinogen

Nostrum Laboratories Inc., based in Kansas City, Missouri, announced Monday that it is voluntarily recalling its metformin HCl extended release tablets, USP 750 mg, according to a recall posted by the US Drug & Food Administration.
Testing revealed levels of nitrosamine, or NDMA, above acceptable limits in the recalled tablets.
The chemical NDMA is considered a possible carcinogen by the US Environmental Protection Agency. It’s an organic chemical used to make liquid rocket fuel and it can be a byproduct of manufacturing, including pharmaceutical manufacturing. It’s also found in water and foods, including meats, dairy and vegetables.

NDMA has also been found in certain blood pressure drugs and antacid.

This is the latest in a series of metformin recalls linked to potentially cancer-causing contaminants in the drugs.

Nostrum said it has not received any reports of adverse events related to the recall. The company also said it was notifying its distributors and arranging for the return of the recalled product.

The impacted product is packaged in HDPE bottles of 100 tablets, under NDC 29033-056-01. The affected Metformin HCl Extended Release Tablets, USP 750 mg lots are under NDC 29033-056-01, lot numbers MET200101 and MET200301 which expiration date 05/2022. It can be identified as an off-white oblong tablet debossed with “NM7.”

More than 34 million people in the US have diabetes — about 1 in 10 — with approximately 90 to 95% of them being diagnosed with type 2 diabetes, according to the US Centers for Disease Control and Prevention.

Source Article

Read more

Cancer Diagnostics Market Research Report by Diagnostic Type, by Indication – Global Forecast to 2025

Cancer Diagnostics Market Research Report by Diagnostic Type (Biopsy and Cytology Test, Diagnostic Imaging Test, and Tumor Biomarkers), by Indication (Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, and Kidney Cancer) – Global Forecast to 2025 – Cumulative Impact of COVID-19

New York, Oct. 26, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Cancer Diagnostics Market Research Report by Diagnostic Type, by Indication – Global Forecast to 2025 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p05913709/?utm_source=GNW

The Global Cancer Diagnostics Market is expected to grow from USD 140,325.96 Million in 2019 to USD 221,237.88 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.88%.

Market Segmentation & Coverage:
This research report categorizes the Cancer Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Diagnostic Type, the Cancer Diagnostics Market studied across Biopsy and Cytology Test, Diagnostic Imaging Test, and Tumor Biomarkers.

Based on Indication, the Cancer Diagnostics Market studied across Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, and Skin Cancer.

Based on Geography, the Cancer Diagnostics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Diagnostics Market including Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson & Company, F. Hoffmann-La Roche Ltd, GE Healthcare, Hologic Inc., Illumina Inc., Philips Healthcare, Qiagen NV, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc..

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer Diagnostics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and

Read more

Cellular Health Screening Market Research Report by Test Type, by Sample Type – Global Forecast to 2025

Cellular Health Screening Market Research Report by Test Type (Heavy Metal Tests, Inflammation Tests, Multi-test Panels, Oxidative Stress Tests, and Telomere Tests), by Sample Type (Blood and Body Fluids) – Global Forecast to 2025 – Cumulative Impact of COVID-19

New York, Oct. 23, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Cellular Health Screening Market Research Report by Test Type, by Sample Type – Global Forecast to 2025 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p05913784/?utm_source=GNW

The Global Cellular Health Screening Market is expected to grow from USD 2,031.33 Million in 2019 to USD 3,740.69 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 10.71%.

Market Segmentation & Coverage:
This research report categorizes the Cellular Health Screening to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Test Type, the Cellular Health Screening Market studied across Heavy Metal Tests, Inflammation Tests, Multi-test Panels, Oxidative Stress Tests, and Telomere Tests.

Based on Sample Type, the Cellular Health Screening Market studied across Blood and Body Fluids.

Based on Geography, the Cellular Health Screening Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cellular Health Screening Market including Bio-Reference Laboratories Inc., Cell Science Systems Corporation, Cleveland HeartLab Inc., Genova Diagnostics Inc., Laboratory Corporation of America Holdings, Life Length S.L., Quest Diagnostics Incorporated, and SpectraCell Laboratories Inc.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cellular Health Screening Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering

Read more

Childhood Absence Epilepsy Treatment Market Research Report by Drug, by Disease Type – Global Forecast to 2025

Childhood Absence Epilepsy Treatment Market Research Report by Drug (Lamotrigine, Phase 2 Drugs, and Valproate), by Disease Type (Atypical Absence Seizures and Typical Absence Seizures) – Global Forecast to 2025 – Cumulative Impact of COVID-19

New York, Oct. 22, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Childhood Absence Epilepsy Treatment Market Research Report by Drug, by Disease Type – Global Forecast to 2025 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p05913817/?utm_source=GNW

The Global Childhood Absence Epilepsy Treatment Market is expected to grow from USD 181.92 Million in 2019 to USD 263.89 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.39%.

Market Segmentation & Coverage:
This research report categorizes the Childhood Absence Epilepsy Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug, the Childhood Absence Epilepsy Treatment Market studied across Lamotrigine, Phase 2 Drugs, and Valproate.

Based on Disease Type, the Childhood Absence Epilepsy Treatment Market studied across Atypical Absence Seizures and Typical Absence Seizures.

Based on Geography, the Childhood Absence Epilepsy Treatment Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Childhood Absence Epilepsy Treatment Market including AbbVie, Cavion, Inc., GlaxoSmithKline plc, Insys Therapeutics, Pfizer Inc., Pfizer Inc., and Teva Pharmaceutical Industries Ltd..

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Childhood Absence Epilepsy Treatment Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain,

Read more

Coffee, Green Tea Might Extend Life for Folks With Type 2 Diabetes | Health News

By Serena Gordon
HealthDay Reporter

(HealthDay)

THURSDAY, Oct. 22, 2020 (HealthDay News) — If you’ve got type 2 diabetes and love drinking green tea or coffee, new research suggests you may be reducing your odds of a premature death.

But you need to really love these drinks. The study found that having four or more cups of green tea along with two cups of coffee daily was linked to a 63% lower risk of death during the average five-year follow-up.

On their own, a single cup of coffee or green tea daily might lower your risk of early death by 12% to 15%, respectively.

“Familiar beverages such as green tea and coffee may have health-promoting effects. We have shown that higher consumption of green tea and coffee was associated with reduced all-cause mortality, and their combined effect appeared to be additive in people with type 2 diabetes,” said lead author Dr. Yuji Komorita, an assistant professor at Kyushu University’s Graduate School of Medical Sciences in Fukuoka, Japan.

Komorita said it’s unknown how either drink may aid health. Both contain nutrients that may reduce inflammation, among other healthful benefits. Since coffee and green tea together were linked to an even lower risk of early death, Komorita suggested that each may have different beneficial substances that act on different diseases.

But Komorita added an important caveat: This study was not designed to prove cause and effect. As an observational study, it can only find an association.

Komorita also pointed out that researchers didn’t have a lot of information about participants that could affect the findings, such as their education, income and family history.

The study included almost 5,000 Japanese adults (average age: 66) with type 2 diabetes. Almost 2,800 were men. Their health was followed for about 5 years.

Participants completed a lengthy food and drink questionnaire that asked how much green tea and coffee they had daily. They were also asked lifestyle questions, such as how much exercise they did, alcohol and smoking habits, and how much sleep they typically got.

Only about 600 participants didn’t drink green tea. About 1,000 didn’t drink coffee.

Of those who sipped green tea, more than 1,100 drank up to a cup a day, almost 1,400 had two to three and nearly 1,800 drank four or more cups each day, the findings showed. For coffee drinkers, 1,300 had up to a single cup daily, more than 960 had one cup and 1,660 had two or more a day.

During the follow-up period, just over 300 participants died.

Compared to people who didn’t drink either beverage, participants who had green tea or coffee were less likely to die during the study, the researchers found. Those who drank both had the largest reductions in death risk.

And, the more you drank, the lower your odds of dying, the study found. Folks who had more than four cups of green tea daily had a 40% lower risk — the same as those who had two or more cups

Read more

Clostridium Vaccine Market Research Report by Animal Type, by Distribution Channel – Global Forecast to 2025

Clostridium Vaccine Market Research Report by Animal Type (Bovine, Ovine, Poultry, and Swine), by Distribution Channel (Hospitals, Veterinary Clinics, and Veterinary Research Institute) – Global Forecast to 2025 – Cumulative Impact of COVID-19

New York, Oct. 22, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Clostridium Vaccine Market Research Report by Animal Type, by Distribution Channel – Global Forecast to 2025 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p05913851/?utm_source=GNW

The Global Clostridium Vaccine Market is expected to grow from USD 416.46 Million in 2019 to USD 591.30 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.01%.

Market Segmentation & Coverage:
This research report categorizes the Clostridium Vaccine to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Animal Type, the Clostridium Vaccine Market studied across Bovine, Ovine, Poultry, and Swine.

Based on Distribution Channel, the Clostridium Vaccine Market studied across Hospitals, Veterinary Clinics, and Veterinary Research Institute.

Based on Geography, the Clostridium Vaccine Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Clostridium Vaccine Market including ARKO laboratories, Bayer AG, Bimeda, Inc., Boehringer Ingelheim, Ceva logistics, Colorado Serum Company, Merck & Co. Inc., Nuovo Biologics, LLC, Virbac, and Zoetis Services LLC.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Clostridium Vaccine Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant

Read more